Significant variability in critical study parameters such as tumor incidences and survival, increasing tumor incidence and decreasing survival in common toxicity test models, and agent-induced changes in body weight (BW) and BW distribution all generate concern about the reproducibility, consistency, and equity of chronic toxicity tests used in regulation. These concerns have led to suggestions to control BW in chronic tests by the modulation of dietary intake without inducing malnutrition [dietary control (DC)] thereby minimizing tumor and survival variability both between and within studies. Evaluating the reports of the best controlled set of chronic experiments, the National Toxicology Program bioassay series, from studies initiated from 1981 to 1990, there is an increase in tumor incidence, especially liver tumors, with a consistent increase in BW. The studies are classified as to whether normal or aberrant BW growth curves occur. When the studies with normal growth curves are considered, the variance in the BW at 12 mo on test (BW12) can account for over 50% of the variance in liver tumor incidence. Additional stratification by study type, which alter tumor prevalences, as well as appreciation of housing effects [group housing decreases survival (in male mice) and induces tumors in males and females when compared to individual housing], further increase the strength of the correlations, accounting for up to 90% of the variance seen in tumor incidences. These updated analyses further support the hypothesis that it is the BW variation that is resulting in much of the variability seen in tumor incidences and refine the suggestions for the BW curves used as the desired targets for DC.
INTRODUCTION
Chronic toxicity tests are critical to the estimation of the risks associated with regulated products (1, 6) . To make equitable, scientifically based assessments, the toxicity tests that underlie them should be reliable, reproducible, and consistent. Study consistency has been brought into question because of the significant experiment-to-experiment variability seen in toxicity tests in critical parameters such as survival and incidences of common tumors (14, 18, 21) . This is true even for the best monitored and controlled chronic bioassays, those conducted by the National Toxicology Program (NTP) (3, 18, 20, 21) . In addition to the variability seen in these parameters (4, 21) , there appear to have been time-related increases in the incidences of liver and pituitary tumors in female mice from 1971 to 1980, which do not appear to be a result of changing diagnostic criteria (13) . Similar, more pronounced, changes over the same time period were observed in Fischer-344 (F-344) rats, as well as increases in thyroid C-cell tumors, adrenal pheochromocytomas, and leukemia in males and mammary tumors in females (12) . In male rats, both F-344 (12) and Sprague-Dawley (8, 9) , time-related significant decreases in sur- vival have been reported. These changes were associated with an increase in average body weight (BW) or food consumption. Recent (16, (20) (21) (22) and survival (25) .
Given the relationship of BW to tumor incidence and survival, Turturro et al (22) suggested the use of dietary control (DC), that is, the modulation of BW by the control of dietary intake without inducing malnutrition, in order to reduce variability in survival and tumor incidence and prevent the increase of tumor incidences in the future. It was also suggested that the BW growth curves to use as the target or desired result of DC be based on allowing a reasonable background tumor incidence of common tumors, neither so high as to confound test interpretation by the presence of inordinate levels of background tumor incidences nor so low as to bring into question the sensitivity of the animals to induction of tumors.
To develop these suggestions further, these more comprehensive analyses were undertaken using more recent NTP data. The analyses reported here will discuss 1 of the 2 species used in the NTP bioassays, the B6C3F1 mouse.
METHODS
The methods are similar to those used in Turturro et al (22) . BWs were average BW at different times-on-test from approximately 50 animals. Control animal BWs were evaluated in all the NTP bioassays using B6C3F1 1 mice whose initial dosing started since 1981 and was reported up to June 1996, a total of 107 bioassays (each study is identified by a technical report [TR] number). (10, 11) ], and evaluations were made using the untreated control animals in these studies. The reports are available from NTP Central Data Management, NIEHS, PO. Box 12233, MD AO-01, Research Triangle Park, North Carolina 27709. When TR numbers are repeated, it indicates that the study contained multiple controls and was used more than once. (i) indicates inhalation studies, (f) indicates feed studies, (c) indicates corn oil gavage studies, (g) indicates water gavage studies, (w) indicates drinking water studies, and (d) indicates dermal studies. &dquo;Abnormal&dquo; BW curves, identified by a second letter in the type of study, are divided into 2 classes: (n) indicates significant variability in the BW growth curves (especially nonmonotonic behavior) and (r) indicates an unchanging BW after 9 mo to 1 yr, on test (i.e., no normal growth).
Four studies were excluded from further analysis: TR410 because it did not report BW tables, TR384 because it reported only the combined incidence of tumors for both the mice that underwent interim sacrifice and those that underwent terminal sacrifice, TR349 because there was a widespread uterine infection, and TR350 because there was a 50% mortality and pregnancy in animals segregated by sex (the latter 2 situations suggest significant control problems were encountered), leaving 103 studies in the database. The TR numbers of these studies are listed in Table I . Also listed are whether the bioassays were feed studies, corn oil gavage studies, or other. Thirty-five of the studies in the database have &dquo;abnor-mal&dquo; BW growth curves, that is, are different from what is usually seen in either 2-yr or other chronic studies using these animals. These &dquo;abnormal&dquo; curves can be divided into 2 classes. Fifteen studies, marked with an (n) in Table I , have significant fluctuation in their BW growth curves, with regions where the BW curves are nonmonotonic or peak erratically. Twenty studies, identified as (r) in Table I , report little or no BW increase between 9 and 12 mo on test until the end of the 24-mo test period, suggesting some unusual effect of the experimental conditions on the BW of the animals. This latter phenomenon is also observed when dietary restriction (DR) is performed (17, 19, 20, 24) . The remaining 68 studies comprise the &dquo;normal&dquo; subset of studies.
The NTP studies start between 6 and 11 wk of age, and the animals are weighed at various weeks after study initiation. To maximize comparability across studies, the BW used for different times-on-test were the values for the week closest to the weeks-on-test plus 8 wk (to approximate an average age of study initiation).
Because the focus of these analyses was the use of this information in risk assessment, the tumor incidences used were the combined incidence of adenoma and carcinoma (i.e., total tumor incidence) while lymphoma incidence included all malignant forms of the disease. To address the problem of animals dying before they can express tumors, the Kaplan-Meier adjusted incidence, that is, the incidence adjusted for intercurrent mortality, when available, was used, derived from the statistical analyses sections of each bioassay report. When tumor incidences were below the reporting requirements of these sections (generally less than 8%), the value was estimated by counting the number of tumors in the individual animal tumor reports and estimating the Kaplan-Meier adjustment from the data presented in the analyses.
Standard statistical methods are used to derive regression curves, and comparisons between groups are made with t-tests. For those relationships between BW and tumor incidence that are nonlinear, r is the square root of the variance in the incidence accounted for by the BW variable.
RESULTS AND DISCUSSION
Changes over Time As shown in Figs. 1 and 2, tumor incidences (e.g., in the liver) have continued to vary in NTP studies initiated from 1981 to 1990 in B6C3F1 mice. Similar wide ranges of variability are seen for lung tumors and survival, as well as for pituitary tumors in female mice (data not shown). Based on the studies initiated from 1981 to January 1987 (because so few studies initiated after January 1987 have been reported so far, they may not adequately represent yearly range or average), it also appears that the range of incidence between studies has increased, especially for females. As also shown in Figs. I and 2, there has been a yearly increase in the average liver tumor incidence of 3.9% in males and 7.3% in females, with the resultants that the FiG. I.-Liver tumor incidence for control male B6C3F1 mice in NTP chronic studies that initiated chronic dosing from 1981 to 1990 and were reported to June 1996. Each marker is a study with at approximately 50 animals. (g) (A) indicates group-housed animals, (b) (0) indicates studies in which the animals were initially group-housed and later separated to prevent fighting, and (i) (A) indicates studies in which the animals were individually housed for the duration of the study. (r) is a correlation coefficient, which is significant at p < 0.001. 1981 incidence increased by 63% in males and increased 5-fold in females by the beginning of 1987. These increases have been accompanied by a yearly increase in the BW at 12 mo on test (BW12) (a good predictor of liver tumor incidence) of 0.93 g in males ( Fig. 3 ) and 1.96 g in females (Fig. 4 ). In addition, there has been a yearly 1.7% increase in lung tumors in male mice. Interestingly, there has been an average yearly decrease of 1.5% in lymphoma incidence in male and 1.4% in female mice from 1981 to 1987. However, these changes have occurred concomitant with the increased use of and were reported to June 1996. Each marker is a study with at approximately 50 animals. (g) (D) indicates group-housed animals, (b) (0) indicates studies in which the animals were initially group-housed and later separated, and (i) (0) indicates studies in which the animals were individually housed for the duration of the study. (r) is a correlation coefficient, which is significant at p < 0.001. mice in NTP chronic studies that initiated chronic dosing from 1981 to 1990 and were reported to June 1996. Legend is the same as Fig. 1 [1] [2] [3] [4] and extended to females to increase comparability between studies. When comparable individual and group-housed studies are evaluated (Table II) , group housing of animals results in almost doubling the lymphoma incidence in both males and females, with significant declines in survival in male mice and a suggestion of the same effect in females (these data correct and extend a similar table in Turturro et al (22) in which the titles of the columns were inadvertently switched). When the lymphoma incidences are evaluated from 1984 to 1987 (when individual housing was used extensively for both males and females), there is no decrease in lymphoma incidence with time in both sexes. Thus, group housing of animals seems to have adverse consequences for the animals' health. (TR443, TR442, TR435, TR433, TR430, TR427, TR424,  TR422, TR420, TR420, TR418, TR416, TR414, TR387, TR348) or group  (TR428, TR415, TR404, TR402, TR401, TR398, TR395, TR394, TR391, TR388,  TR365, TR357, TR356 , TR355, TR353) housing in males and 13 studies in females (the same studies as males, except TR387 and TR348, because in these studies the females were group-housed and, consequently, two fewer group-housed studies for comparison, TR355 and TR353).
* Significantly different at least at the <0.01 level.
Tumor Incidences and BW
There is a strong correlation between liver tumor incidence and BW12 in male ( Fig. 5 ) and female ( Fig. 6 ) mice using the studies in this database, similar to what has been reported earlier (20) (21) (22) . The correlations improve if the studies with normal growth curves are considered separately, with over half the variance in the liver tumor incidence accounted for by the variance in BW12.
These data demonstrate what occurs in a long-term study under conditions of normal growth. In studies with little normal growth after 9-12 mo on test ([aber r] in Figs. 5 and 6), the slope of the relationship of BW12 and tumor incidence is approximately two-thirds of the slope of the curve for the normal studies (i.e., less steep), indicating that the predicted incidence of liver tumors is less than that expected when normal growth occurs. Relationships of tumor incidences to BW at different times on test also occur for lung tumors, lymphomas, and, in female mice, pituitary tumors (data not shown). As indicated previously (21) , the type of experiment (e.g., gavage or feed study) impacts the control incidences of tumors. This is illustrated in Table III for some common tumors and an indicator BW. Because the type of study can impact upon tumor incidence, when the different study types are considered separately, the correlations are stronger than those seen for all studies combined. This is illustrated in Fig. 7 for inhalation studies in male mice, in Fig. 8 for feed studies in female mice, and in Fig. 9 for lung tumors in corn oil gavage studies in male mice (For lung tumors, BW at 9 mo on test [BW9] is the best predictor of total lung tumor incidence at the end of a 2-yr study).
Impact on Study Interpretation
Because much of the variance in tumor incidence is a result of the variance in BW, when a restricted BW range is considered the variation in tumor incidence among studies is also restricted. This is illustrated for corn oil gavage studies in females in Fig. 10 . From 38 to 42 g, BW12 liver tumor incidences in the studies vary between 14 and 28%. This is much less than the range of 5-50% when the studies are not stratified by BW. This limitec range makes the use of the historical tumor database (3 14) much more useful to monitor study quality and asp with aberrant growth similar to studies with intentional DR, and (0) are studies that have significant nonmonotonic BW growth curves (see Table I and text). The regression line of total studies and the normal studies are so similar that the curve for the normal studies was not presented to aid clarity. The dashed line is the regression curve of the (aber r) studies (A), which is shallower, with approximately two-thirds the slope of the total (or normal) studies. Both (r)'s are significant at p < 0.001.
propriateness. For instance, if the controls for the female mice in a corn oil gavage study with an average BW12 of 40 reports a liver tumor incidence of 5%, or 45%, there is reason to look carefully at the study to see whether or not some uncontrolled factor is complicating the interpretation of the liver tumor incidences in that study.
Consideration of the variation between studies in BW
FiG. 6.-Relationship of BW12 and liver tumor incidence in control female B6C3F1 mice. (S) are studies with normal BW growth, (0) are studies with aberrant growth similar to studies with intentional DR, and (0) are studies that have significant nonmonotonic BW growth curves (see Table I and text). The regression line of total studies and the normal studies are so similar that the curve for the normal studies was not presented to aid clarity. The dotted line is the regression curve of the (aber r) studies (D), which is shallower, with approximately two-thirds the slope of the total (or normal) studies. Both r's are significant at p < 0.001. Table I . Liver care. is liver carcinoma incidence. Study types are the same as in Table I (the 2 dermal studies were not included in this analysis). Number is the number of studies of each type. bede on the same row, significantly different at the p < 0.01 level; x on the same row, significantly different at the p < 0.05 level. and associated tumor incidences has also brought to the fore the effect of BW variation within a study. The range of BW variation in a study can be large, as illustrated in Fig. 11 . This variability also exists in animals exposed to agent. Just as the incidence of tumors can be correlated across studies with BW12, individual liver tumor risk can be estimated to be a quadratic function of BW12 (16) .
The consequence of these observations is that the distribution of BW in a study may be useful to consider in interpretation. For instance, if a compound exposure results in a BW distribution in which half of the animals are large and the other half small, the predicted value of liver tumors in this dose group is higher than the value in a control with animals close to the mean BW.
More common than changes in BW distribution, there is also a change induced by agent in average BW in toxicity tests. Inhibition of BW gain induced by agents can inhibit tumor incidence, as demonstrated in the bioassay of amphetamine (11) , in which dosing with the stimulant resulted in lower liver tumor incidences than controls in a dose-dependent manner concomitant with the lowered BW gain in dosed animals observed during the study.
A number of solutions have been proposed to the problems of increasing tumor incidences and decreasing survival in long-term toxicity tests (2) . Many appear to cause more problems than they solve. For instance, there has been a suggestion to breed small size into the animals by selecting the smaller breeding pairs to parent the next generation. The changes in the animals genome that could result from the selection to achieve a small size (e.g., impairment of food absorption, increased incidence of kidney disease) can complicate the interpretation of toxicity studies, and these new &dquo;strains&dquo; will probably not be similar in toxic response to older studies with the &dquo;same&dquo; animal. The only practical, comprehensive solution to these problems, which also does not change the genetic characteristics of the animals and addresses the problems of variability among and within chronic toxicity tests is the control of BW through control of dietary intake without malnutrition, or DC.
To estimate the impact of DC, it should be appreciated that there are more than 60 yr of studies that have characterized the effects of restricting growth on survival and tumorigenesis [e.g., Turturro and Hart (23) (17) ] in addition to the NTP studies discussed earlier. To produce weight gains in an experiment that are slow enough so that survival is enhanced and tumors inhibited, yet fast enough so that response to tumorigenic agents is uncompromised is not a simple task [e.g., see Kari and Abdo (7) ]. Based on the type of analyses used in this paper, some suggestions for the conduct of studies utilizing DC have already been made, including the use of individual housing for animals and target BW curves for certain types of studies, in male and female animals, for different species (22) . The more comprehensive analyses presented here will be used to update and modify the target weight curves for test animals. Also, by extending the previous analyses over longer times, these efforts further support the concept that uncontrolled dietary intake, resulting in highly variable BW, is a major factor in the variability seen in chronic toxicity tests.
CONCLUSION
In this study, the variability and increase in tumor incidences and BW in male and female B6C3F1 mice in the NTP bioassays, some of the best controlled of all toxicity tests, for 1981-1990 were demonstrated, with some evidence that the range of variability in tumor incidences also has been increasing. The relationship of certain BW, such as BW12 and BW9, to tumor incidences in toxicity tests has been illustrated, while these relationships have been shown to be different when experiments do not achieve normal BW growth patterns but instead show patterns similar to those that occur with intentional DR. The tumorigenic effect of group housing of animals has been shown, as well as the adverse impact upon survival in male mice. Different study types seem to impact tumor incidences, and when the relationships of time-ontest-specific BW and tumors take this factor into account, these relationships become particularly strong. In certain Table I. The area around 40 g BW12 is highlighted, indicating that the range in this region is significantly less than the range for the entire corn oil gavage studies. (r) is significant at p < 0.001. cases, the variance in the BW can account for 90% of the variance in tumor incidence.
These data taken together further support the hypothesis that variability in BW, a result of ad libitum feeding in rodent chronic toxicity tests, is an important factor in the variability in test controls and the increase in tumor incidences and decreases in survival seen in many rodent tests strains. In addition, these unchecked variations also complicate test result interpretation when agent administration results in changes in either average BW or BW distribution.
Given the consequences of uncontrolled BW growth, it is critical that this factor be brought under control. The simplest, most feasible approach to achieve this appears FiG. 11.-The BW12 distribution for a typical NTP study in male B6C3F1 mice. The study is the control for the bioassay of pentaerythritol tetranitrate (9) , with individual BW for the study, as used in Seilkop (16) . The bar height denotes the number of animals at each 1 gram weight (e.g., for 40 g BW12, it is the number of animals with BW12 between 39.50 and 40.49 g). to be the imposition of DC to target weight curves. This procedure, which would automatically regulate the studyto-study variation in BW, also has the benefits of limiting variation within a study (through the imposition of DC on the most rapid individual growth rates) and allowing the test chemical to be evaluated with mitigation of the complicating factors associated with agent-induced BW loss. The individual housing that also is required by this procedure results in better control of individual animal agent exposure as well as prevention of behavioral induced complications, such as trauma resulting from fighting.
DC appears to be important to assure the consistency of the chronic bioassay from test to test, much as there are needs to control the effect of individual investigator differences by the use of Pathology Working Groups or to control the differences in environmental conditions and procedures in the conduct of histopathological assays. Also, there is no a priori need to wade through a great deal of background pathology or risk compromising a long-term toxicity study simply because there was no control on the adverse effects of diets fed ad libitum under current conditions. It appears to be simply a question of whether one wishes to control one of the most potent parameters in animal health and toxic response or to allow uncontrolled and uncontrollable factors such as environmental conditions, animal husbandry conditions, and so forth to alter this parameter and complicate the interpretations of the results of a chronic toxicity test.
